BIOMEA FUSION INC. -

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2024 15:05:51 By Nasdaq GlobeNewswire

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

30 Oct 2024 15:00:48 By Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

29 Oct 2024 15:46:08 By Nasdaq GlobeNewswire

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

21 Oct 2024 08:00:29 By Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

15 Oct 2024 15:05:19 By Nasdaq GlobeNewswire

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

07 Oct 2024 08:00:41 By Nasdaq GlobeNewswire

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

01 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

26 Sep 2024 13:00:57 By Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2024 15:05:20 By Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

31 Jul 2024 15:05:22 By Nasdaq GlobeNewswire

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

06 Jun 2024 15:05:53 By Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2024 15:05:29 By Nasdaq GlobeNewswire

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

30 May 2024 08:12:39 By Nasdaq GlobeNewswire

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

02 May 2024 15:05:01 By Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 May 2024 15:10:28 By Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2024 15:10:59 By Nasdaq GlobeNewswire

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

01 Apr 2024 08:02:04 By Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

01 Apr 2024 08:00:11 By Nasdaq GlobeNewswire

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

06 Mar 2024 02:04:51 By Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 15:16:34 By Nasdaq GlobeNewswire